Skip to main content
OpenTrials
Completed

NCT Number: NCT01265797

Cranial Electrotherapy Stimulation in the Treatment of Migraine Headaches

Cranial electrotherapy stimulation (CES) may be a safe adjunct to medical treatment for pain relief in migraine patients. However, despite the number of CES studies done, many have been open label, single blinded, or have utilized a small group of patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Toledo, Health Science Campus

Toledo, Ohio, 43614, United States

About this study

This study will evaluate the efficacy of the Fisher Wallace Cranial Stimulator in persons with chronic migraine who have not achieved satisfactory pain control on their current medications.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects satisfying the IHS (International Headache Society) criteria for migraine
  • Subjects have not achieved satisfactory pain control on their current medication
  • Ability to maintain a daily headache diary
  • Stable medication use related to migraine for at least 4 weeks prior to enrollment in the study

Exclusion criteria

  • Previous exposure to or experience with cranial electrotherapy stimulation (CES)
  • Contraindications to Fisher Wallace stimulator, such as cardiac pacemakers or implantable defibrillators, known or suspected heart disease, or pregnancy
  • Seizure disorders

Treatment and study plan

Cranial Electrostimulator

Device

participant wears active cranial electrostimulation device for 20 minutes daily for 28 days

Other names: Fisher Wallace Cranial Electrostimulator

Sham device

Device

participant wears sham device for 20 minutes daily for 28 days

Primary outcomes

  1. Mean Headache Days

    Time frame: 28 day period during run-in month and blinded month

    Mean change in headache days between 28 day run-in month and 28 day blinded month, i.e. run-in month mean minus blinded month mean. A good response is >= 50% reduction in headache days (congruent with the Guidelines for Trial of Behavioral Treatments for Recurrent Headache).

  2. Depression Score (PATIENT HEALTH QUESTIONNAIRE [PHQ] 9)

    Time frame: 14 days recall; measured at end of run-in month and blinded month

    Mean difference of PHQ-9 score between the run-in month and blinded month, i.e. PHQ-9 score from run-in month minus blinded month. The PHQ-9 is a tool for assisting in diagnosing depression (over the prior 2 week period) as well as selecting and monitoring treatment. There are nine items, with responses each ranging from 0 (not at all) to 3 (nearly every day), for a total range of 0 to 27. The higher the total the more severe the depressive symptoms.

Secondary outcomes

  1. Headache Days

    Time frame: 28 day period in run-in month and open label month

    Mean change in headache days between 28 day run-in month and 28 day open label month, i.e. run-in month mean minus open label month mean. A good response is >= 50% reduction in headache days (congruent with the Guidelines for Trial of Behavioral Treatments for Recurrent Headache).

  2. Depression Score (Patient Health Questionnaire-9)

    Time frame: 14 day recall, recorded at the end of run-in and open label months

    Mean difference of PHQ-9 score between the run-in month and open label month, i.e. PHQ-9 score from run-in month minus open label month. The PHQ-9 is a tool for assisting in diagnosing depression (over the prior 2 week period) as well as selecting and monitoring treatment. There are nine items, with responses each ranging from 0 (not at all) to 3 (nearly every day), for a total range of 0 to 27. The higher the total the more severe the depressive symptoms.

  3. Headache Impact Test-6

    Time frame: after run-in month, after blinded month

    Mean difference in HIT-6 score between run-in month and blinded month. The HIT-6 is a tool for screening and monitoring change in headache disability. This disease-specific health survey is intended for adults 18 years of age and older, and is available with a standard four-week recall period. It is a 6 item questionnaire with scores for each item ranging from 6 (never) to 13 (always). The minimum overall score is 36 and the maximum is 78. Higher scores represent greater disability.

  4. Headache Impact Test (HIT-6) (Measure of Disability Due to Headaches)

    Time frame: 28 day period in run-in month and open label month

    Mean difference in HIT-6 score between run-in month and open label month. The HIT-6 is a tool for screening and monitoring change in headache disability. This disease-specific health survey is intended for adults 18 years of age and older, and is available with a standard four-week recall period. It is a 6 item questionnaire with scores for each item ranging from 6 (never) to 13 (always). The minimum overall score is 36 and the maximum is 78. Higher scores represent greater disability.

  5. Generalized Anxiety Disorder Score (GAD 7)

    Time frame: 14 days recall; measured at end of run-in month and blinded month

    Mean difference in GAD 7 score between run-in month and blinded month. This is a screening tool and severity measure for generalized anxiety disorder addressing symptoms over the prior 2 weeks. It is a 7 item questionnaire with response scores for each item ranging from 0 (not at all) to 3 (every day). The range for the total score is 0 to 21, with higher scores representing greater symptoms of anxiety

  6. Generalized Anxiety Disorder Score (GAD 7)

    Time frame: 14 day recall, recorded at the end of run-in and open label months

    Mean difference in GAD 7 score between run-in month and open label month. This is a screening tool and severity measure for generalized anxiety disorder addressing symptoms over the prior 2 weeks. It is a 7 item questionnaire with response scores for each item ranging from 0 (not at all) to 3 (every day). The range for the total score is 0 to 21, with higher scores representing greater symptoms of anxiety

  7. Somatic Symptom Severity (Patient Health Questionnaire 15)

    Time frame: 28 days recall; measured at end of run-in month and blinded month

    Mean difference in PHQ 15 score between run-in month and blinded month. The PHQ-15 comprises 15 somatic symptoms experienced over the prior 4 weeks and their severity, each symptom scored from 0 ("not bothered at all") to 2 ("bothered a lot"). The range for the overall score is between 0 and 30, with higher score representing more severe somatic symptoms

  8. Somatic Symptom Score (Patient Health Questionnaire-15)

    Time frame: 28 day period in run-in month and open label month

    Mean difference in PHQ 15 score between run-in month and open label month. The PHQ-15 comprises 15 somatic symptoms experienced over the prior 4 weeks and their severity, each symptom scored from 0 ("not bothered at all") to 2 ("bothered a lot"). The range for the overall score is between 0 and 30, with higher score representing more severe somatic symptoms.

  9. Epworth Sleepiness Scale Score

    Time frame: recorded at the end of run-in month and blinded month

    Mean difference of Epworth Sleepiness Scale score between run-in month and blinded month. The Epworth Sleepiness Scale is used to measure excessive daytime sleepiness. This is an 8 item questionnaire, recalling probability of falling asleep in "recent times". The subjects are asked to rate probability of falling asleep in eight different situations. The score for each item ranges from 0 (would never doze) to 3 (high chance of dozing), with the overall score range of 0 to 24. Higher scores represent higher probability of falling asleep.

  10. Epworth Sleepiness Scale Score

    Time frame: Score recorded at the end of run-in and open label month

    Mean difference of Epworth Sleepiness Scale score between run-in month and open label month. The Epworth Sleepiness Scale is used to measure excessive daytime sleepiness. This is an 8 item questionnaire, recalling probability of falling asleep in "recent times". The subjects are asked to rate probability of falling asleep in eight different situations. The score for each item ranges from 0 (would never doze) to 3 (high chance of dozing), with the overall score range of 0 to 24. Higher scores represent higher probability of falling asleep.

Sponsors and collaborators

Lead sponsor

University of Toledo Health Science Campus

Other

Registry information

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Dec 23, 2010
Registry last updated
Feb 10, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.